Clinical TrialAug 6, 2026, 07:08 AM
Monte Rosa Activates 2 Phase 2 Trials; MRT-8102 Data H2 2026; Q2 Net Loss $43.4M
AI Summary
Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4 million and collaboration revenue of $9.0 million. The company activated two new Phase 2 clinical trials: MODeFIRe-1 for MRT-2359 in mCRPC and a Novartis-led study for MRT-6160 (DDY391) in Sjögren’s disease. Monte Rosa also completed enrollment for the GFORCE-1 study of MRT-8102, with data expected in H2 2026, and plans to initiate multiple additional Phase 2 studies for MRT-8102. The company maintains a strong cash position of $626.0 million, expected to fund operations into 2029.
Key Highlights
- Activated MODeFIRe-1 Phase 2 study of MRT-2359 in mCRPC.
- Novartis activated Phase 2a/b study for MRT-6160 (DDY391) in Sjögren’s disease.
- Completed enrollment for GFORCE-1 Phase 1 study of MRT-8102; data H2 2026.
- Plans to initiate multiple MRT-8102 Phase 2 studies in H2 2026, Q4 2026/Q1 2027, and H1 2027.
- Q2 2026 Net Loss was $43.4 million, compared to $12.3 million in Q2 2025.
- Q2 2026 Collaboration Revenue was $9.0 million, down from $23.2 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $626.0 million.
- Cash position expected to support operations into 2029.
Price Impact
More from GLUE